MA-NETSCOUT-SYSTEMS
21.9.2021 12:03:07 CEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report that underscore the dramatic impact cyberattacks continue to have on private and public organizations and governments worldwide. In the first half of 2021, cybercriminals launched approximately 5.4 million Distributed Denial of Services (DDoS) attacks, increasing 11% over 1H2020 figures. Additionally, data projections from NETSCOUT's Active Level Threat Analysis System (ATLAS™) Security Engineering and Response Team (ASERT) point to 2021 as another record-setting year on track to surpass 11 million global DDoS attacks. ASERT expects this long tail of attacker innovation to last, fueling a growing cybersecurity crisis that will continue to impact public and private organizations.
In the wake of Colonial Pipeline, JBS, Harris Federation, Australian broadcaster Channel Nine, CNA Financial, and several other high-profile attacks, the impact of DDoS and other cybersecurity attacks has been felt worldwide. As a result, leading governments are introducing new programs and policies to defend against attacks, and policing organizations are initiating unprecedented collaborative efforts to address the crisis.
During 1H2021, cybercriminals weaponized and exploited seven newer reflection/amplification DDoS attack vectors putting organizations at greater risk. This attack vector explosion spurred an increase in multivector DDoS attacks with a record-setting 31 attack vectors deployed in a single attack against one organization.
Other key findings from the NETSCOUT 1H2021 Threat Intelligence Report include:
- New adaptive DDoS attack techniques evade traditional defenses. By customizing their strategies, cybercriminals evolved their attack efforts to bypass cloud-based and on-premise static DDoS defenses to target commercial banks and credit card processors.
- Connectivity supply chain increasingly under attack. Bad actors looking to cause the most collateral damage focused their efforts on vital internet components, including DNS servers, virtual private network (VPN) concentrators, services, and internet exchanges, disrupting essential gateways.
- Cybercriminals add DDoS to their toolkit to launch triple extortion campaigns. Ransomware has become big business, with extortionists adding DDoS to their attack regimen to ratchet up the pressure on victims and add stress to security teams. Triple extortion combines file encryption, data theft, and DDoS attacks, increasing the possibility that cyber criminals receive payment.
- The fastest DDoS attack recorded a 16.17% year-over-year increase. A Brazilian wireline broadband internet user launched the attack, which was likely related to online gaming. Using DNS reflection/amplification, TCP ACK flood, TCP RST flood, and TCP SYN/ACK reflection/amplification vectors, the sophisticated attack recorded 675 Mpps.
- The largest DDoS attack, 1.5 Tbps, represented a year-over-year increase of 169%. ASERT data identified this attack against a German ISP, deploying a DNS reflection/amplification vector. This attack represents a dramatic increase in size over any attacks recorded in 1H2020.
- Botnets contribute to major DDoS activity - Tracked botnet clusters and high-density attack-source zones worldwide showcased how malicious adversaries abused these botnets to participate in more than 2.8 million DDoS attacks. In addition, well-known IoT botnets Gafgyt and Mirai continue to pose a severe threat contributing to more than half of the total number of DDoS attacks.
"Cybercriminals are making front-page news launching an unprecedented number of DDoS attacks to take advantage of the pandemic's remote work shift by undermining vital components of the connectivity supply chain," stated Richard Hummel, threat intelligence lead, NETSCOUT. "Ransomware gangs added triple-extortion DDoS tactics to their repertoire. Simultaneously, the Fancy Lazarus DDoS extortion campaign kicked into high gear threatening organizations in multiple industries with a focus on ISPs and specifically their authoritative DNS servers."
NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data secured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with NETSCOUT's ATLAS Security Engineering & Response Team (ASERT) insights.
The visibility and analysis represented in the Threat Intelligence Report and Omnis® Threat Horizon fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security product portfolio to detect and block threat activity for enterprises and service providers worldwide.
For more information on NETSCOUT's semi-annual Threat Intelligence Report, please visit our interactive website . You can also find us on Facebook , LinkedIn, and Twitter for threat updates and the latest trends and insights.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Our Omnis® cybersecurity advanced threat detection and response platform offers comprehensive network visibility, threat detection, highly contextual investigation, and automated mitigation at the network edge. NETSCOUT nGenius™ service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.
©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005395/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
